Mechanistic studies of high-density lipoproteins.

Abstract

There is increasing evidence that high-density lipoprotein (HDL) and its subfractions are protective against atherosclerotic cardiovascular disease. Physical exercise, weight reduction, smoking cessation, diabetes mellitus control, and specific drugs, including niacin, fibrates, and estrogens, are effective methods to increase HDL levels. Niacin is the oldest and most powerful clinical agent for raising HDL levels. Niaspan, an extended-release niacin formulation, is as potent as immediate-release niacin in increasing levels of HDL cholesterol; subfractions HDL2 and HDL3; apolipoprotein A-I, the major protein of HDL, and its cardioprotective subfraction lipoprotein A-I. Recent research from our laboratory suggests a novel mechanism by which niacin inhibits hepatic removal of HDL-apoprotein A-I without interfering with the removal of cholesterol carried by HDL, thus augmenting reverse cholesterol transport. Other mechanistic studies indicate that fibrates and estrogens stimulate the synthesis and production of HDL-apoprotein A-I. Because niacin decreases HDL-apoprotein A-I removal, and fibrates and estrogens increase HDL-apoprotein A-I production, combinations of niacin with these agents may raise HDL levels more than fibrates or estrogens alone.

• Authors: M L Kashyap
• Journal: The American journal of cardiology (Am J Cardiol) Vol. 82 Issue 12A Pg. 42U-48U; discussion 85U-86U (Dec 17 1998) ISSN: 0002-9149 [Print] United States
• PMID: 9915662 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Apolipoprotein A-I
• Delayed-Action Preparations
• Lipoproteins, HDL
• Niacin

Topics

• Apolipoprotein A-I (drug effects, metabolism)
• Delayed-Action Preparations
• Humans
• Hypolipoproteinemias (classification, drug therapy)
• Lipoproteins, HDL (blood, drug effects, metabolism)
• Niacin (pharmacology)